The role of AKT1 in enhancing the capacity of both glycolytic and oxidative metabolism, thereby maintaining bioenergetic levels after treatments such as BRAF inhibition, makes it an important factor to study and potentially target to limit the plasticity of melanoma cells. The gene discussed is BRAF; the disease is melanoma.